FDA expands Vabysmo (Faricimab) label for retinal vein occlusion, allowing treatment beyond six months and supporting long-term, continuous care for patients with vision-threatening macular edema.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Genentech, a member of the Roche Group, has secured approval from the U.S. Food and Drug Administration to expand the label of Vabysmo for the treatment of macular edema due to retinal vein occlusion beyond six months. The update allows continued therapy for patients who are benefiting from treatment, reinforcing long-term disease management in a condition that often requires chronic intravitreal injections.
RVO affects more than one million Americans and can lead to persistent macular edema and vision impairment. Treatment typically involves repeated anti-VEGF injections, and therapy changes may disrupt disease control. The updated label enables clinicians to maintain Vabysmo therapy beyond the previous six-month window, supporting continuity of care and reducing the need for switching therapies.
“This label update reinforces our commitment to delivering consistent, long-term solutions for patients with vision impairment,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. He added that Vabysmo’s established efficacy should help minimize disruptive treatment switches in patients with RVO who are responding well to therapy.
According to Veeral Sheth, M.D., partner and director of clinical research at University Retina and Macula Associates, the updated dosing provides retina specialists with greater flexibility. Aligning the label with real-world practice allows clinicians to tailor treatment intervals and deliver more seamless, continuous care aimed at supporting long-term visual outcomes.
Vabysmo is the first bispecific antibody approved for ophthalmic use. It targets both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), two pathways implicated in vascular instability, leakage, and inflammation in retinal diseases. By simultaneously inhibiting Ang-2 and VEGF-A, the therapy is designed to stabilize blood vessels and reduce fluid accumulation in the retina.
In the United States, Vabysmo is approved for adults with neovascular (wet) age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. The expanded RVO label further positions the therapy as a long-term treatment option across multiple vision-threatening retinal conditions.
Reference
FDA approves updated Vabysmo label to extend treatment for macular edema following retinal vein occlusion (RVO) beyond six months, 09 April 2026, https://www.gene.com/media/statements/ps_040926
About the Writer
Samiksha Vikram Jadhav is a B.Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She has a keen interest in healthcare advancements, clinical research, medical writing, and emerging therapies. Her work focuses on presenting developments in the pharmaceutical and healthcare sectors through clear and accurate scientific communication.